Bionomics Reports the Commencement of P-III (AFFIRM-1) Study Evaluating BNC210 for Social Anxiety Disorder (SAD)
Shots:
- Bionomics has commenced the screening for P-III (AFFIRM-1) study of BNC210 (225mg) vs PBO for acute treatment of SAD among 330 adults in ratio 1:1 across the US
- The 1EP includes change in SUDS scores from baseline to the public speaking performance phase; 2EPs are change in SUDS score and changes in the Clinical Global Impression – Severity (CGI-S) scale & self-assessment with the State-Trait Anxiety Inventory (STAI, State subscale) as well as the Patient-Global Impression - Improvement (PGI-I) scale
- BNC210 is a fast-acting, non-sedating, non-addictive, and non-cognition impairing α7 nicotinic receptor small molecule, developed for acute & chronic use in neuropsychiatric disorders
Ref: Bionomics | Image: Bionomics
Related news:- Bionomics Reports P-II Study (PREVAIL) Results of BNC210 for the Treatment of Social Anxiety Disorder
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
